ABUS vs CVS
Arbutus Biopharma Corp (ABUS) versus CVS Health Corp (CVS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Not investment advice. Open the ABUS and CVS stock pages for the full models.
Not investment advice.